MESO Mesoblast Limited

6.08
+0.08  (+1%)
Previous Close 6
Open 6
Price To Book 1.25
Market Cap 602,073,465
Shares 99,025,241
Volume 31,481
Short Ratio
Av. Daily Volume 52,913
Stock charts supplied by TradingView

NewsSee all news

  1. Mesoblast Completes Successful Institutional Capital Raising of A$75 Million

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)), leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a A$75 million (US$50.4

  2. Mesoblast Corporate Update: Analyst Call

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in cellular medicines for inflammatory diseases, will provide a corporate update during an analyst call today. The

  3. Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain

    AACHEN, Germany, and MELBOURNE, Australia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Grünenthal, a global leader in pain management, and Mesoblast Limited ((ASX: MSB, NASDAQ:MESO), a world leader in allogeneic cellular

  4. Mesoblast Reports 2019 Full Year Results

    NEW YORK and MELBOURNE, Australia, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)) today reported strong operational progress and financial highlights for the fourth quarter and full-year

  5. Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019

    NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in cellular medicines for inflammatory diseases, will host a webcast to discuss the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b Class IV primary endpoint reached 1Q 2018.
MPC-150-IM - Class IV
Chronic heart failure (CHF)
Phase 3 data due mid-2020.
MPC-06-ID
Chronic low back pain
Rolling BLA has been filed. To be completed 4Q 2019.
MSC-100-IV
acute graft versus host disease (aGVHD) in children
Phase 2 data released August 2016. Partnership required for Phase 3 development.
MPC-300-IV
Rheumatoid arthritis
Phase 3 data due 1H 2020.
MPC-150-IM - Class 2/3
Heart failure
Phase 2b trial did not meet primary endpoint - November 11, 2018.
MPC-150-IM
End-Stage Heart Failure with LVADs

Latest News

  1. Mesoblast Completes Successful Institutional Capital Raising of A$75 Million

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)), leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a A$75 million (US$50.4

  2. Mesoblast Corporate Update: Analyst Call

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in cellular medicines for inflammatory diseases, will provide a corporate update during an analyst call today. The

  3. Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain

    AACHEN, Germany, and MELBOURNE, Australia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Grünenthal, a global leader in pain management, and Mesoblast Limited ((ASX: MSB, NASDAQ:MESO), a world leader in allogeneic cellular

  4. Mesoblast Reports 2019 Full Year Results

    NEW YORK and MELBOURNE, Australia, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)) today reported strong operational progress and financial highlights for the fourth quarter and full-year

  5. Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019

    NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in cellular medicines for inflammatory diseases, will host a webcast to discuss the

  6. FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD

    NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in cellular medicines for inflammatory diseases, announced today positive outcomes from its